Evidence map›Paper›PMID 29212839›Full record

Trial reportJournal of the American Society of Nephrology : JASN2018

BP in Dialysis: Results of a Pilot Study.

Dana C Miskulin, Jennifer Gassman, Ronald Schrader, Ambreen Gul, Manisha Jhamb, David W Ploth, Lavinia Negrea, Raymond Y Kwong, Andrew S Levey, Ajay K Singh and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Guideline
  2. Higher blood pressure targets for hypertension in older adults.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Guideline
  7. Dialysate Sodium Lowering in Maintenance Hemodialysis: A Randomized Clinical Trial.Clinical journal of the American Society of Nephrology : CJASN · 2024
    Trial
  8. A randomized controlled trial of two dialysate sodium concentrations in hospitalized hemodialysis patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Trial
  9. Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Trial
  10. Review
  11. Article
  12. Article
  13. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  14. Combined blood pressure and pulse rate as a new risk marker for mortality in hemodialysis patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  15. Blood Pressure and Risk of Clinical Events in Peripheral Artery Disease.medRxiv : the preprint server for health sciences · 2025
    Article
  16. Volume Assessment in Patients Undergoing Long-Term Dialysis.Journal of the American Society of Nephrology : JASN · 2025
    Review
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dana C MiskulinDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Jennifer GassmanDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Ronald SchraderQuality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico.
Ambreen GulQuality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico.
Manisha JhambRenal-Electrolyte Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
David W PlothDepartment of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina.
Lavinia NegreaDivision of Nephrology and Hypertension, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Raymond Y KwongRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.
Andrew S LeveyDivision of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts.
Ajay K SinghRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.
Antonia HarfordQuality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico.
Susan PaineQuality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico.
Cynthia KendrickDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Mahboob RahmanDivision of Nephrology and Hypertension, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Philip ZagerQuality Management Department, Dialysis Clinic, Inc., Albuquerque, New Mexico; pzag@unm.edu.

Funding

Blood Pressure in Dialysis PatientsR01DK083424 · NIDDK · UNIVERSITY OF NEW MEXICO · PI MISKULIN, DANA C, PLOTH, DAVID W · 2010 to 2012
$1.6M
NIDDK NIH HHS R01 DK083424
6 · The paper itself

Abstract

The optimal BP target for patients receiving hemodialysis is unknown. We randomized 126 hypertensive patients on hemodialysis to a standardized predialysis systolic BP of 110-140 mmHg (intensive arm) or 155-165 mmHg (standard arm). The primary objectives were to assess feasibility and safety and inform the design of a full-scale trial. A secondary objective was to assess changes in left ventricular mass. Median follow-up was 365 days. In the standard arm, the 2-week moving average systolic BP did not change significantly during the intervention period, but in the intensive arm, systolic BP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months. From months 4-12, the mean separation in systolic BP between arms was 12.9 mmHg. Four deaths occurred in the intensive arm and one death occurred in the standard arm. The incidence rate ratios for the intensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.87 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular access thrombosis, respectively. The intensive and standard arms had similar median changes (95% confidence intervals) in left ventricular mass of -0.84 (-17.1 to 10.0) g and 1.4 (-11.6 to 10.4) g, respectively. Although we identified a possible safety signal, the small size and short duration of the trial prevent definitive conclusions. Considering the high risk for major adverse cardiovascular events in patients receiving hemodialysis, a full-scale trial is needed to assess potential benefits of intensive hypertension control in this population.

Indexed as

Blood PressureRenal DialysisAdultAgedAnastomosis, SurgicalAntihypertensive AgentsArteriesBody WeightCardiovascular DiseasesFemaleHospitalizationHumansHypertensionHypertrophy, Left VentricularHypotensionMaleAntihypertensive Agentsblood pressurehemodialysishypertensionrandomized controlled trials

Identifiers

PMID29212839
PMCPMC5748902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.